^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    golidocitinib (DZD4205)

    i
    Other names: DZD4205, AZD-4205, AZD 4205, AZD4205, DZD-4205
    Company:
    Dizal Pharma
    Drug class:
    JAK1 inhibitor
    Related drugs:
    5d
    Prospective Single-Arm Clinical Trial of GO Regimen for HLH. (clinicaltrials.gov)
    P2/3, N=28, Recruiting, Beijing Friendship Hospital
    New P2/3 trial
    |
    golidocitinib (DZD4205)
    6d
    EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, Sun Yat-sen University
    New P1/2 trial
    |
    Epidaza (chidamide) • zeprumetostat (SHR-2554) • golidocitinib (DZD4205)
    19d
    Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=101, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Epidaza (chidamide) • golidocitinib (DZD4205) • Duoenda (mitoxantrone liposomal)
    20d
    A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) (clinicaltrials.gov)
    P2, N=90, Recruiting, Dizal Pharmaceuticals | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Zegfrovy (sunvozertinib) • golidocitinib (DZD4205)
    24d
    JACKPOT22: Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer (clinicaltrials.gov)
    P2, N=16, Not yet recruiting, The First Affiliated Hospital of Guangzhou Medical University
    New P2 trial
    |
    golidocitinib (DZD4205)
    26d
    AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) (clinicaltrials.gov)
    P2, N=57, Completed, Dizal Pharmaceuticals | Recruiting --> Completed | N=150 --> 57 | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: May 2025 --> Oct 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    golidocitinib (DZD4205)
    27d
    T-START-M1: Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma (clinicaltrials.gov)
    P3, N=136, Not yet recruiting, Fudan University
    New P3 trial
    |
    golidocitinib (DZD4205)
    28d
    Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia (clinicaltrials.gov)
    P1/2, N=42, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1/2 trial
    |
    golidocitinib (DZD4205)
    1m
    Golidocitinib Combined With GemOx in RR PTCL (clinicaltrials.gov)
    P2, N=31, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    oxaliplatin • golidocitinib (DZD4205)
    2ms
    A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) (clinicaltrials.gov)
    P3, N=218, Recruiting, Dizal Pharmaceuticals
    New P3 trial
    |
    gemcitabine • Epidaza (chidamide) • Beleodaq (belinostat) • Folotyn (pralatrexate) • golidocitinib (DZD4205)
    3ms
    Prospective, Multicenter, Single-Arm Clinical Study of Golidocitinib Combined with CMOP Regimen in the Treatment of Previously Untreated Young Patients with Peripheral T-Cell Lymphoma (PTCL) (ChiCTR2500109697)
    P=N/A, N=45, Not yet recruiting, The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University
    New trial
    |
    golidocitinib (DZD4205)
    3ms
    A prospective, single-arm,multicenter center clinical study of JAK1 inhibitor Golidocitinib combined with steroid as first-line treatment for chronic graft-versus-host disease patients with high risk of steroid therapy failure. (ChiCTR2500108541)
    P4, N=40, Not yet recruiting, The Second Affiliated Hospital of Army Medical University (Xinqiao Hospital of Army Medical University); The Second Affiliated Hospital of Army Medica
    New P4 trial
    |
    prednisone • golidocitinib (DZD4205)